High Court in Dublin Rules in Pfizer's Favor in Patent Case, Lipitor Protected From Generic Competition Until 2011
Posted on: Tuesday, 10 July 2007, 06:16 CDT
Pfizer Inc said today that the High Court in Dublin, Ireland has ruled that the basic patent covering atorvastatin - the active ingredient in Lipitor - would be infringed by a competitor product from generics manufacturer Ranbaxy. The decision, which is subject to a possible appeal, prevents Ranbaxy from launching its drug before the basic Lipitor patent (Irish Patent Number 60014) expires in November 2011.
"Today's decision is yet another affirmation of the strength of the intellectual property behind Lipitor," said Pfizer General Counsel Allen Waxman. "It also is an important outcome for Pfizer and other medical innovators who invest in high-risk research to develop life-saving medicines, and for the patients who benefit from those medicines."
Source: Business Wire
Related Articles
- Pfizer Wins Lipitor Patent Case Against Ranbaxy
- Ruling Upholds Pfizer's Lipitor Patent
- Spanish Court Rules in Pfizer's Favor on Lipitor Patent Challenge
- Lipitor Patent Win Boosts Pfizer Shares
- Pfizer Stock Up on Lipitor Patent Victory
- Pfizer's Lipitor Patent Upheld
- Pfizer Shares Rise on Lipitor Patent Win
- Pfizer Prevails in Challenges to Lipitor Patents in the United States
- Pfizer Wins Lipitor Patent Challenge in UK
- Pfizer Prevails in Challenge to Basic Lipitor Patent in British High Court
 |
 |
User Comments (0)
RSS Feeds